Abstract
Vascular disrupting agents (VDAs) are a new class of potential anticancer drugs that selectively destroy tumor vasculature and shutdown blood supply to solid tumors, causing extensive tumor cell necrosis. VDAs target established tumor blood vessels, which are distinct from antiangiogenic agents that prevent the formation of new blood vessels. There are two types of VDAs, small molecules and ligand-directed agents. Most of the small molecule VDAs are tubulin inhibitors, including CA4P, ZD6126, AVE8062, OXi-4503, NPI-2358, MN-029 and EPC2407. The others are synthetic flavonoids including FAA and DMXAA that induce the production of local cytokines such as TNF-alpha. VDAs have shown good antitumor efficacy in animal models, especially in combination with established anticancer agents. Several VDAs, including CA4P and DMXAA, have demonstrated good safety profile as well as some promising efficacy in phase I clinical trials. Currently CA4P and DMXAA are in phase II clinical trials and AVE8062, OXi-4503, NPI-2358 and MN- 029 are in phase I clinical trials. This review will focus on recent progress in the discovery and development of small molecule VDAs, including recently published patent applications and issued patents related with small molecule VDAs.
Keywords: Vascular disrupting agents (VDAs), anticancer drugs, small molecule, tubulin inhibitors, synthetic flavonoids, CA4P, DMXAA, ZD6126, AVE8062, OXi-4503
Recent Patents on Anti-Cancer Drug Discovery
Title: Small Molecule Vascular Disrupting Agents: Potential New Drugs for Cancer Treatment
Volume: 2 Issue: 1
Author(s): Sui X. Cai
Affiliation:
Keywords: Vascular disrupting agents (VDAs), anticancer drugs, small molecule, tubulin inhibitors, synthetic flavonoids, CA4P, DMXAA, ZD6126, AVE8062, OXi-4503
Abstract: Vascular disrupting agents (VDAs) are a new class of potential anticancer drugs that selectively destroy tumor vasculature and shutdown blood supply to solid tumors, causing extensive tumor cell necrosis. VDAs target established tumor blood vessels, which are distinct from antiangiogenic agents that prevent the formation of new blood vessels. There are two types of VDAs, small molecules and ligand-directed agents. Most of the small molecule VDAs are tubulin inhibitors, including CA4P, ZD6126, AVE8062, OXi-4503, NPI-2358, MN-029 and EPC2407. The others are synthetic flavonoids including FAA and DMXAA that induce the production of local cytokines such as TNF-alpha. VDAs have shown good antitumor efficacy in animal models, especially in combination with established anticancer agents. Several VDAs, including CA4P and DMXAA, have demonstrated good safety profile as well as some promising efficacy in phase I clinical trials. Currently CA4P and DMXAA are in phase II clinical trials and AVE8062, OXi-4503, NPI-2358 and MN- 029 are in phase I clinical trials. This review will focus on recent progress in the discovery and development of small molecule VDAs, including recently published patent applications and issued patents related with small molecule VDAs.
Export Options
About this article
Cite this article as:
Cai X. Sui, Small Molecule Vascular Disrupting Agents: Potential New Drugs for Cancer Treatment, Recent Patents on Anti-Cancer Drug Discovery 2007; 2 (1) . https://dx.doi.org/10.2174/157489207779561462
DOI https://dx.doi.org/10.2174/157489207779561462 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Heat Shock Protein Inhibitors for the Treatment of Fungal Infections
Recent Patents on Anti-Infective Drug Discovery The Physiology of Nitric Oxide: Control and Consequences
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents A Point of View: The Need to Identify an Antigen in Psyconeuroimmunological Disorders
Current Pharmaceutical Design Genetics and Epigenetics Mechanism in the Pathogenesis of Behçet’s Disease
Current Rheumatology Reviews Meet Our Editorial Board Member
Endocrine, Metabolic & Immune Disorders - Drug Targets Differential TNF-Signaling in Chronic Inflammatory Disorders
Current Molecular Medicine Control of Protein Synthesis in Malignant Transformation - the Role of eIF4E and the eIF4E Binding Proteins in the Regulation of Apoptosis
Current Cancer Therapy Reviews Immunogenicity and its Impact on Benefit/Risk Considerations in the Authorisation of Biopharmaceuticals
Current Drug Safety Neurophysiological Mechanisms Related to Pain Management in Bone Tumors
Current Neuropharmacology Targeting Mitochondrial Bioenergetics for Alzheimers Prevention and Treatment
Current Pharmaceutical Design Meet the Editorial Board:
Technology Transfer and Entrepreneurship (Discontinued) Update on SAR Studies Toward New COX-1 Selective Inhibitors
Current Medicinal Chemistry Antibody Fusion Proteins: Applications in Brain Targeting
Current Medicinal Chemistry - Central Nervous System Agents Irbesartan: Second Generation of ARB as Metabosartan
Current Hypertension Reviews Developing Solid Particulate Vaccine Adjuvants: Surface Bound Antigen Favours a Humoural Response, whereas Entrapped Antigen Shows a Tendency for Cell Mediated Immunity
Current Drug Delivery Recent Advances in the Development of Immunoadhesins for Immune Therapy and as Anti-Infective Agents
Recent Patents on Anti-Infective Drug Discovery Topical Delivery of Antioxidants
Current Drug Delivery Recent Progress in the Design and Discovery of RXR Modulators Targeting Alternate Binding Sites of the Receptor
Current Topics in Medicinal Chemistry Pathogenesis of Neointima Formation Following Vascular Injury
Cardiovascular & Hematological Disorders-Drug Targets Metastasis-Inducing S100A4 Protein: Implication in Non-Malignant Human Pathologies
Current Molecular Medicine